Psoriatic ArthritisspanishTopasNCT01891903
to Translate and Validate the TOPAS TORONTO PSORIATIC SCREENING QUESTIONNAIRE)Into Spanish
An observational study of Psoriatic Arthritis, run by Reumatologia Integral LTDA at 1 site in Colombia.
Trial summary
TO TRANSALETE AND VALIDATE DE TORONTO PSORIATIC ARTHRITIS SECREENING QUESTIONAIRE INTO SPANISH Read more about this study
- Who is it for?
- Ages 16 years and older
- Conditions the study is for
- Psoriatic Arthritis
- How many people
- 60 participants
- Where
- 1 siteColombia
- Study dates
- May 2013to Sep 2013
- How long will I take part?
- 20 Days
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: PATIENTS WITH PSORIASIS ASESSED IN THE DERMATOLOGY CLINIC
Who may be able to join
- ADULT WITH PSORIASIS IN THE DERMATOLOGY CLINIC
Who cannot join
- ADULT WITH OTHER AUTOIMMUNE DISEASE
Trial locations and contacts
1 site in 1 country.
Colombia1 site, 1 recruiting
- Recruiting
Hospital Universitario Clinica San Rafael
Bogota, Cundinamarca, 12345
ADRIANA BELTRAN, RHEUMATOL, 0573134327730, adribeltr@yahoo.com
About this study
Official title: TO TRANSLATE AND VALIDATE THE ToPAS (TORONTO PSORIATIC SCREENING QUESTIONNAIRE) FOR THE SCREENING OF PSORIATHIC ARTHRITIS PATIENTS IN DERMATOLOGY CLINICS
TO TRANSALETE AND VALIDATE DE TORONTO PSORIATIC ARTHRITIS SECREENING QUESTIONAIRE INTO SPANISH
Read the detailed description
THIS IS PART OF THE COLOMBIAN REGISTRY OF PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS
- Conditions
- Psoriatic Arthritis
- Medical subject headings
- Arthritis, Psoriatic
What is being measured
The primary outcome is the main question the study is designed to answer.
The Kuder Richardson Coefficient of reliability (K-R 20)
Measured: 4 MONTHS
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jul 2013 (estimated)
- Study startMay 2013
- Primary completionAug 2013 (estimated)
- Study completionSep 2013 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Psoriatic ArthritisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Time perspective
- Prospective
- Enrolment
- 60 participants (estimated)
- Target duration
- 20 Days
Sponsor and investigators
- Lead sponsor
- Reumatologia Integral LTDA
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Adriana Beltran, Reumatologia Integral LTDA
- Investigators
- Daniel Fernandez, rheumatolo, Study director, hospital san ignasio
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01891903
- Sponsor's protocol ID
- TOPAS52424166
- Acronym
- spanishTopas
- Status last verified
- Jun 2013
- First submitted
- 18 Jun 2013
- Last updated
- 3 Jul 2013
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 3 Jul 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- TO TRANSLATE AND VALIDATE THE ToPAS (TORONTO PSORIATIC SCREENING QUESTIONNAIRE) FOR THE SCREENING OF PSORIATHIC ARTHRITIS PATIENTS IN DERMATOLOGY CLINICS
- ClinicalTrials.gov ID
- NCT01891903
- Acronym / sponsor ID
- spanishTopas / TOPAS52424166
- Conditions
- Psoriatic Arthritis
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Reumatologia Integral LTDAUniversity, hospital or other
- Study start
- May 2013
- Primary completion
- Aug 2013 (estimated)
- Study completion
- Sep 2013 (estimated)
- First posted
- 3 Jul 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
TO TRANSALETE AND VALIDATE DE TORONTO PSORIATIC ARTHRITIS SECREENING QUESTIONAIRE INTO SPANISH
Detailed description
THIS IS PART OF THE COLOMBIAN REGISTRY OF PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS
Study design
- Time perspective
- Prospective
- Target follow-up
- 20 Days
Who may qualify
- Ages
- 16 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- PATIENTS WITH PSORIASIS ASESSED IN THE DERMATOLOGY CLINIC
Key inclusion criteria (1 listed)
- ADULT WITH PSORIASIS IN THE DERMATOLOGY CLINIC
Key exclusion criteria (1 listed)
- ADULT WITH OTHER AUTOIMMUNE DISEASE
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The Kuder Richardson Coefficient of reliability (K-R 20)
Time frame: 4 MONTHS
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Jul 2013.
Related trials for Psoriatic Arthritis
RecruitingPhase 1
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
Psoriatic Arthritis, Axial Spondyloarthritis
Recruiting
Efficacy of a Self-Management Smartphone App to Improve Safety Skills in Patients With Inflammatory Arthritis
Rhumatoid Arthisis, Spondyloarthritis (SA)
Not yet recruitingPhase 2
Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)
Moderate to Severe Psoriatic Arthritis
Active, not recruitingPhase 3
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
Psoriatic Arthritis
RecruitingPhase 4
Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial
Psoriatic Arthritis (PsA)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Daniel Fernandez, rheumatolo study director
hospital san ignasio
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Psoriatic Arthritis, run by Reumatologia Integral LTDA at 1 site in Colombia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 3 Jul 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Colombia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The Kuder Richardson Coefficient of reliability (K-R 20) (time frame: 4 MONTHS). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jul 2013; AzTrials last refreshed its copy on 7 Nov 2026.